Clinical Trials
ABBVIE Alzheimer’s ‘Aware’ Study
The primary purpose of this phase II multiple dose, multicenter, randomized, double-blind, placebo-controlled study is to evaluate the efficacy and safety of ABBV-8E12, an anti-tau antibody, in subjects with Alzheimer’s Disease.
What can you expect?
People with Alzheimer’s disease have abnormal tau protein in their brains. Doctors and scientists think the build-up of tau protein may worsen Alzheimer’s symptoms. The Aware Study is being conducted to learn if the investigational medication may block the spreading of tau protein in the brain and slow down the progression of Alzheimer’s disease.
Subjects enrolled in this placebo-controlled study will receive monthly infusions over the course of two years, after which they will be eligible for a five-year open-label “extension study”, on which every subject receives the drug.
The Principal investigator for the study is Dr. Lealani Acosta MD, MPH.
Recruitment for the original study is now inactive across the globe, and enrollment into the extension study is available only for those subjects who completed treatment on the original protocol.
For more detailed information on this study please contact:
Elizabeth Farr
Clinical Translational Research Coordinator II
Phone: (615) 322-2267
Email: elizabeth.l.farr@vumc.org